FDA Press Release - FDA Approves Therapy To Treat Gaucher Disease

New drug will offer a treatment alternative for patients with rare genetic disorder

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

See the FDA's full press release here.

SOURCE U.S. Food and Drug Administration